Citations

Clear

3485 citation(s) found for "Sy, Sarah".

DNA mismatch repair gene MSH6 implicated in determining age at natural menopause
Perry, John R. B. , Hsu, Yi-Hsiang, Johnson, Andrew D. , Elks, Cathy E., Albrecht, Eva, Andrulis, Irene L. , Berenson, Gerald S., Bojesen, Stig E. , Bolla, Manjeet K. , Brown, Judith, Buring, Julie E. , Campbell, Harry, Chang‐Claude, Jenny , Chenevix‐Trench, Georgia , Corre, Tanguy , Cox, Angela , Czene, Kamila , D’Adamo, Pio , Davies, Gail , Deary, Ian J. , Easton, Douglas F. , Engelhardt, Ellen G. , Eriksson, Johan G. , Fasching, Peter A. , Figueroa, Jonine D. , Flyger, Henrik, Fraser, Abigail , García‐Closas, Montserrat , Gasparini, Paolo , Gieger, Christian , Giles, Graham G. , Guénel, Pascal , Hägg, Sara , Hayward, Caroline , Hopper, John L. , investigators, kConFab, Kardia, Sharon L. R., Kasiman, Katherine, Knight, Julia A. , Lahti, Jari , Lawlor, Debbie A. , Magnusson, Patrik K. E. , Margolin, Sara , Marsh, Julie , Polašek, Ozren , Rahman, Iffat , Ridker, Paul M., Robino, Antonietta , Rudan, Igor , Salumets, Andres , Schmidt, Marjanka K. , Schoemaker, Minouk J. , Smith, Erin N. , Smith, Jennifer A. , Southey, Melissa C. , Stöckl, Doris, Swerdlow, Anthony J. , Thompson, Deborah J. , Truong, Thérèse , Ulivi, Sheila , Waldenberger, Mélanie , Wang, Qin , Wright, Alan F., Zgaga, Lina , Karasik, David , Murray, Anna , Uitterlinden, André G. , Hsu, Yi‐Hsiang , Chasman, Daniel I. , Beesley, Jonathan , Bergmann, Sven M. , Couch, Fergus J. , Dennis, Joe , Esko, Tõnu , Hall, Per N , Ingelsson, Erik , investigators, kConFab, Metspalu, Andres , Olson, Janet E. , Pennell, Craig Edward , Rudolph, Anja , Wild, Sarah H. , Wilson, James Fox , Ong, Ken K. , Murabito, Joanne M. , Giles, Graham G , Swerdlow, Anthony J , Smith, Jennifer A , Southey, Melissa C , Cox, Angela , Guénel, Pascal , García-Closas, Montserrat , Schmidt, Marjanka K , Chenevix-Trench, Georgia , Figueroa, Jonine D , Czene, Kamila , Bojesen, Stig E , Schoemaker, Minouk J , Truong, Therese

Mayo Clinic

Human Molecular Genetics | December 20, 2013 | Volume: 23 | Issue: 9 | Pages: 2490-2497

10.1093/hmg/ddt620 | PMID 24357391 Get It

Impact of Patient Portal Secure Messages and Electronic Visits on Adult Primary Care Office Visits
North, Frederick , Crane, Sarah J. , Chaudhry, Rajeev , Ebbert, Jon O. , Ytterberg, Karen L., Tulledge‐Scheitel, Sidna M. , Stroebel, Robert J.

Mayo Clinic

Telemedicine and e-Health | December 18, 2013 | Volume: 20 | Issue: 3 | Pages: 192-198

10.1089/tmj.2013.0097 | PMID 24350803 Get It

Introduction: Secure messages and electronic visits (“e-visits”) through patient portals provide patients with alternatives to face-to-face appointments, telephone contact, letters, and e-mails. Limited information exists on how portal messaging impacts face-to-face visits in primary care. Materials and Methods: We conducted a retrospective cohort study of 2,357 primary care patients who used electronic messaging (both secure messages and e-visits) on a patient portal. Face-to-face appointment frequencies (visits/year) of each patient were calculated before and after the first message in a matched-pairs analysis. We analyzed visit frequencies with and without adjustments for a first message surge in visits, and we examined subgroups of high message utilizers and long-term users. Results: Primary care patients who sent at least one message (secure message or e-visit) had a mean of 2.43 (standard deviation [SD] 2.3) annual face-to-face visits before the first message and 2.47 (SD 2.8) after, a nonsignificant difference ( p =0.45). After adjustment for a first message surge in visits, no significant visit frequency differences were observed (mean, 2.35 annual visits per patient both before and after first message; p =0.93). Subgroup analysis also showed no significant change in visit frequency for patients with higher message utilization or for those who had used the messaging feature longer. Conclusions: No significant change in face-to-face visit frequency was observed following implementation of portal messaging. Secure messaging and e-visits through a patient portal may not result in a change of adult primary care face-to-face visits.
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Hicks, Lisa K. , Bering, Harriet, Carson, Kenneth R. , Kleinerman, Judith, Kukreti, Vishal , Ma, Alice , Mueller, Brigitta U., O’Brien, Sarah H. , Pasquini, Marcelo C. , Haynes, Adam E., Hicks, Lisa K. , Sarode, Ravi , Solberg, Lawrence A. , Crowther, Mark Andrew

Mayo Clinic

Hematology | December 6, 2013 | Volume: 2013 | Issue: 1 | Pages: 9-14

10.1182/asheducation-2013.1.9 | PMID 24319155 Get It

Abstract Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Hicks, Lisa K. , Bering, Harriet, Carson, Kenneth R. , Kleinerman, Judith, Kukreti, Vishal , Ma, Alice , Mueller, Brigitta U., O’Brien, Sarah H. , Pasquini, Marcelo C. , Solberg, Lawrence A. , Haynes, Adam E., Hicks, Lisa K. , Sarode, Ravi , Crowther, Mark Andrew

Mayo Clinic

Blood | December 4, 2013 | Volume: 122 | Issue: 24 | Pages: 3879-3883

10.1182/blood-2013-07-518423 | PMID 24307720 Get It

Abstract Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.
The Implementation of Novel Collaborative Structures for the Identification and Resolution of Barriers to Pluripotent Stem Cell Translation
French, Anna , Suh, Jane, Roberts, Mackenna, Davies, Benjamin M. , Pinedo‐Villanueva, Rafael , Wartolowska, Karolina , Rooke, Kelly, Kramm, Anneke, Judge, Andrew , Chandra, Amit , Hurley, Hannah, Grover, Liam M. , Bingham, Ian, Siegel, Bernard, Rattley, Matt S., Buckler, R. Lee, McKeon, David, Krumholz, Katie, Hook, Lilian , Rikabi, Sarah , Pigott, Rosie, Morys-Carter, Megan M. , Sabokbar, Afsie, Titus, Emily, Laâbi, Yacine, Zahkia, Raymond, Sipp, Douglas , Horne, Robert , Bravery, Christopher A., Williams, David , Wall, Ivan , Snyder, Evan Y., Barker, Richard , Bure, Kim, Reeve, Brock , Brindley, David A. , Morrey, Mark E. , May, Michael E , Lemaı̂tre, Gilles , Karp, Jeffrey M. , Carr, Andrew Jonathan , Horne, Rob

Mayo Clinic

Stem Cells and Development | December 4, 2013 | Volume: 22 | Issue: 1_suppl | Pages: 63-72

10.1089/scd.2013.0403 | PMID 24304079 Get It

Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing—of expertise and/or funding—has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.
Diagnostic Exome Sequencing Identifies Two Novel IQSEC2 Mutations Associated with X‐Linked Intellectual Disability with Seizures: Implications for Genetic Counseling and Clinical Diagnosis
Gandomi, Stephanie, Gonzalez, Kelly, Parra, M., Shahmirzadi, Layla, Pichurin, Pavel N. , Temme, Renee, Dugan, Sarah, Mancuso, James J. , Zeng, Wenqi , Tang, Sha

Mayo Clinic

Journal of Genetic Counseling | December 3, 2013 | Volume: 23 | Issue: 3 | Pages: 289-298

10.1007/s10897-013-9671-6 | PMID 24306141 Get It

AbstractIntellectual disability is a heterogeneous disorder with a wide phenotypic spectrum. Over 1,700 OMIM genes have been associated with this condition, many of which reside on the X‐chromosome. The IQSEC2 gene is located on chromosome Xp11.22 and is known to play a significant role in the maintenance and homeostasis of the brain. Mutations in IQSEC2 have been historically associated with nonsyndromic X‐linked intellectual disability. Case reports of affected probands show phenotypic overlap with conditions associated with pathogenic MECP2, FOXG1, CDKL5, and MEF2C gene mutations. Affected individuals, however, have also been identified as presenting with additional clinical features including seizures, autistic‐behavior, psychiatric problems, and delayed language skills. To our knowledge, only 5 deleterious mutations and 2 intragenic duplications have been previously reported in IQSEC2. Here we report two novel IQSEC2 de novo truncating mutations identified through diagnostic exome sequencing in two severely affected unrelated male probands manifesting developmental delay, seizures, hypotonia, plagiocephaly, and abnormal MRI findings. Overall, diagnostic exome sequencing established a molecular diagnosis for two patients in whom traditional testing methods were uninformative while expanding on the mutational and phenotypic spectrum. In addition, our data suggests that IQSEC2 may be more common than previously appreciated, accounting for approximately 9 % (2/22) of positive findings among patients with seizures referred for diagnostic exome sequencing. Further, these data supports recently published data suggesting that IQSEC2 plays a more significant role in the development of X‐linked intellectual disability with seizures than previously anticipated.
Breast Cancer Survivors' Self-Reported Needs and Preferences of Survivorship Care
Thompson, Carrie A. , Jenkins, Sarah M. , Lackore, Kandace A. , Pruthi, Sandhya , Stan, Daniela , Nes, Lise Solberg

Mayo Clinic

The Breast Journal | November 23, 2013 | Volume: 20 | Issue: 1 | Pages: 107-109

10.1111/tbj.12221 | PMID 24262015 Get It

Telemedicine Barriers Associated with Regional Quality Measures
North, Frederick , Crane, Sarah J. , Takahashi, Paul Y. , Ward, William J. , Tulledge‐Scheitel, Sidna M. , Ytterberg, Karen L., Tangalos, Eric G., Stroebel, Robert J. , Takahashi, Paul

Mayo Clinic

Telemedicine and e-Health | November 9, 2013 | Volume: 20 | Issue: 2 | Pages: 179-181

10.1089/tmj.2013.0167 | PMID 24205836 Get It

Telemedicine practitioners are familiar with multiple barriers to delivering care at a distance. Licensing and reimbursement barriers are well known and are being addressed at national and state levels by the American Telemedicine Association. Another telemedicine barrier comes in the form of quality measures for diabetes. Minnesota medical practices are currently being compared on the proportion of their patients with diabetes who have attained goals for blood pressure, low-density lipoprotein cholesterol, and hemoglobin A1C. The quality measure for blood pressure specifically excludes measurements taken by the patient, thus precluding blood pressure telemonitoring as a way to meet the blood pressure goal. To counter this barrier, advocacy in telemedicine is needed so that telemonitoring as a data collection tool is included in quality measures.
αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain
Malin, Dmitry , Strekalova, Elena, Deal, Allison M. , Ahmad, Abraham Al, Adamo, Bárbara , Miller, C. Ryan , Ugolkov, Andrey , Livasy, Chad, Fritchie, Karen , Blackwell, Kimberly , Ewend, Matt, Shusta, Eric V. , Anders, Carey K. , Petrovič, Vladimír , Deal, Allison , Hamilton, Erika , Geradts, Joseph , Carey, Lisa A. , Cryns, Vincent L.

Mayo Clinic

Clinical Cancer Research | October 16, 2013 | Volume: 20 | Issue: 1 | Pages: 56-67

10.1158/1078-0432.ccr-13-1255 | PMID 24132917 Get It

Abstract Purpose: Basal-like breast tumors are typically (ER/PR/HER2) triple-negative and are associated with a high incidence of brain metastases and poor clinical outcomes. The molecular chaperone αB-crystallin is predominantly expressed in triple-negative breast cancer (TNBC) and contributes to an aggressive tumor phenotype in preclinical models. We investigated the potential role of αB-crystallin in brain metastasis in TNBCs. Experimental Design: αB-crystallin expression in primary breast carcinomas and brain metastases was analyzed by immunohistochemistry among patients with breast cancer with brain metastases. αB-crystallin was overexpressed or silenced in two different TNBC cell lines. The effects on cell adhesion to human brain microvascular endothelial cells (HBMEC) or extracellular matrix proteins, transendothelial migration, and transmigration across a HBMEC/astrocyte coculture blood–brain barrier (BBB) model were examined. In addition, the effects of overexpressing or silencing αB-crystallin on brain metastasis in vivo were investigated using orthotopic TNBC models. Results: In a cohort of women with breast cancer brain metastasis, αB-crystallin expression in primary breast carcinomas was associated with poor overall survival and poor survival after brain metastasis, even among patients with TNBC. Stable overexpression of αB-crystallin in TNBC cells enhanced adhesion to HBMECs, transendothelial migration, and BBB transmigration in vitro, whereas silencing αB-crystallin inhibited these events. αB-crystallin promoted adhesion of TNBC cells to HBMECs, at least in part, through an α3β1 integrin–dependent mechanism. αB-crystallin overexpression promoted brain metastasis, whereas silencing αB-crystallin inhibited brain metastasis in orthotopic TNBC models. Conclusion: αB-crystallin is a novel regulator of brain metastasis in TNBC and represents a potential biomarker and drug target for this aggressive disease. Clin Cancer Res; 20(1); 56–67. ©2013 AACR.